Dual-Band Antenna/AMC Combination for RFID

A novel antenna/Artificial Magnetic Conductor (AMC) combination usable in dual-band Radio Frequency Identification (RFID) tags over metallic objects is presented. A compact and low thickness prototype is manufactured and characterized in terms of return loss and radiation properties in an anechoic chamber both alone and on a metallic plate. The performance exhibited by the presented antenna/AMC prototype is proper for RFID tags on both metallic and nonmetallic objects

Mechanisms of hamstring strain injury: Interactions between fatigue, muscle activation and function

Isolated injury to the long head of biceps femoris is the most common type of acute hamstring strain injury (HSI). However, the precise hamstring injury mechanism (i.e., sprint-type) is still not well understood, and research is inconclusive as to which phase in the running cycle HSI risk is the greatest. Since detailed information relating to hamstring muscle function during sprint running cannot be obtained in vivo in humans, the findings of studies investigating HSI mechanisms are based on modeling that requires assumptions to be made based on extrapolations from anatomical and biomechanical investigations. As it is extremely difficult to account for all aspects of muscle-tendon tissues that influence function during high-intensity running actions, much of this complexity is not included in these models. Furthermore, the majority of analyses do not consider the influence of prior activity or muscular fatigue on kinematics, kinetics and muscle activation during sprinting. Yet, it has been shown that fatigue can lead to alterations in neuromuscular coordination patterns that could potentially increase injury risk. The present critical review will evaluate the current evidence on hamstring injury mechanism(s) during high-intensity running and discuss the interactions between fatigue and hamstring muscle activation and function

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Breast cancer metastatic to bone has a poor prognosis despite recent advances in our understanding of the biology of both bone and breast cancer. This article presents a new approach, the ABC7 regimen (Adjuvant for Breast Cancer treatment using seven repurposed drugs), to metastatic breast cancer. ABC7 aims to defeat aspects of epithelial-to-mesenchymal transition (EMT) that lead to dissemination of breast cancer to bone. As add-on to current standard treatment with capecitabine, ABC7 uses ancillary attributes of seven already-marketed noncancer treatment drugs to stop both the natural EMT process inherent to breast cancer and the added EMT occurring as a response to current treatment modalities. Chemotherapy, radiation, and surgery provoke EMT in cancer generally and in breast cancer specifically. ABC7 uses standard doses of capecitabine as used in treating breast cancer today. In addition, ABC7 uses 1) an older psychiatric drug, quetiapine, to block RANK signaling; 2) pirfenidone, an anti-fibrosis drug to block TGF-beta signaling; 3) rifabutin, an antibiotic to block beta-catenin signaling; 4) metformin, a first-line antidiabetic drug to stimulate AMPK and inhibit mammalian target of rapamycin, (mTOR); 5) propranolol, a beta-blocker to block beta-adrenergic signaling; 6) agomelatine, a melatonergic antidepressant to stimulate M1 and M2 melatonergic receptors; and 7) ribavirin, an antiviral drug to prevent eIF4E phosphorylation. All these block the signaling pathways ? RANK, TGF-beta, mTOR, beta-adrenergic receptors, and phosphorylated eIF4E ? that have been shown to trigger EMT and enhance breast cancer growth and so are worthwhile targets to inhibit. Agonism at MT1 and MT2 melatonergic receptors has been shown to inhibit both breast cancer EMT and growth. This ensemble was designed to be safe and augment capecitabine efficacy. Given the expected outcome of metastatic breast cancer as it stands today, ABC7 warrants a cautious trial

Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells

Melatonin exerts oncostatic effects on different kinds of neoplasias, especially on oestrogen-dependent tumours. Recently, it has been described that melatonin, on the basis of its antioxidant properties, inhibits the growth of glioma cells. Glioma cells express oestrogen receptors and have the ability to synthesise oestrogens from androgens. In the present study, we demonstrate that pharmacological concentrations of melatonin decreases the growth of C6 glioma cells and reduces the local biosynthesis of oestrogens, through the inhibition of aromatase, the enzyme that catalyses the conversion of androgens into oestrogens. These results are supported by three types of evidence. Firstly, melatonin counteracts the growth stimulatory effects of testosterone on glioma cells, which is dependent on the local synthesis of oestrogens from testosterone. Secondly, we found that melatonin reduces the aromatase activity of C6 cells, measured by the tritiated water release assay. Finally, by (RT)–PCR, we found that melatonin downregulates aromatase mRNA steady-state levels in these glioma cells. We conclude that melatonin inhibits the local production of oestrogens decreasing aromatase activity and expression. By analogy to the implications of aromatase in other forms of oestrogen-sensitive tumours, it is conceivable that the modulation of the aromatase by pharmacological melatonin may play a role in the growth of glioblastomas

CARMENES input catalogue of M dwarfs IV. New rotation periods from photometric time series

Aims. The main goal of this work is to measure rotation periods of the M-type dwarf stars being observed by the CARMENES exoplanet survey to help distinguish radial-velocity signals produced by magnetic activity from those produced by exoplanets. Rotation periods are also fundamental for a detailed study of the relation between activity and rotation in late-type stars. Methods. We look for significant periodic signals in 622 photometric time series of 337 bright, nearby M dwarfs obtained by long-time baseline, automated surveys (MEarth, ASAS, SuperWASP, NSVS, Catalina, ASAS-SN, K2, and HATNet) and for 20 stars which we obtained with four 0.2-0.8 m telescopes at high geographical latitudes. Results. We present 142 rotation periods (73 new) from 0.12 d to 133 d and ten long-term activity cycles (six new) from 3.0 a to 11.5 a. We compare our determinations with those in the existing literature; we investigate the distribution of P rot in the CARMENES input catalogue,the amplitude of photometric variability, and their relation to vsin i and pEW(Halfa); and we identify three very active stars with new rotation periods between 0.34 d and 23.6 d.Comment: 34 pages, 43 figures, 2 appendix table

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed. The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18–19, 2021 (http://www.cvot.org)

DIGESTIVE ENZYMES PROFILE IN OCTOPUS VULGARIS PARALARVAE FED WITH ARTEMIA ENRICHED WITH MARINE PHOSPHOLIPIDS

The common octopus (Octopus vulgaris) is an excellent candidate for aquaculture production, however the development of its culture needs to overcome the high paralarvae mortality which points out to zootechnical and nutritional problems. Enhancing the knowledge on paralarvae digestive physiology could increase the possibilities to optimize the diet in order to improve the paralarval growth and survival. In the present study, the effect of fed with Artemia enriched with marine phospholipids on digestive enzyme activity of octopus paralarvae from hatchling and 12 days old paralarvae have been studied